Trump Finally Reclassifies Marijuana as Schedule III—Months After His Big Promise

April 23, 2026

The Long-Awaited Move That Never Quite Happened Until Now

After more than four months of delays, deflection, and administrative foot-dragging that would make a sloth look like an Olympic sprinter, President Donald Trump's Department of Justice finally reclassified marijuana from Schedule I to Schedule III on Thursday morning. Yes, you read that right—this was supposed to happen back in November. But hey, who's counting? Certainly not the acting attorney general, who announced the reclassification with all the fanfare of a tax filing deadline.

Trump signed the executive order directing his attorney general to move marijuana down the Controlled Substances Act ladder way back in November 2025. That's roughly 22 weeks ago, for those keeping score at home. The memo probably got lost somewhere between the coffee machine and the "destroy the deep state" task list, because Thursday was the first time anybody actually did anything about it.

According to reporting from Axios and The Washington Post, the move is designed to "boost medical research" and loosen the federal stranglehold that's been throttling legitimate pharmaceutical research into cannabis's medicinal properties. Turns out, when you make something impossible to study, scientists can't study it. Who knew? The Trump team, apparently, but only after a five-month nap.

What This Actually Means for Researchers and Pharma Bros

Schedule III classification is a massive deal for the pharmaceutical industry. It means researchers can now legally conduct studies on FDA-approved and state-licensed marijuana without federal bureaucrats showing up to ruin the party. It also means universities, hospitals, and private pharma companies can finally tackle questions that have been off-limits: Does cannabis really help with chronic pain? Does it work for epilepsy? Can it replace opioids? All fascinating questions that the government has spent 50 years making illegal to investigate.

The reclassification essentially acknowledges something that states have figured out already: marijuana has legitimate medical applications. California, Colorado, Michigan, and thirty-seven other states have been merrily licensing dispensaries and selling pot to anyone with a legitimate medical condition for years while the federal government stood on the sidelines muttering about Schedule I status.

The Trump administration's move isn't exactly revolutionary—it's basically admitting the war on drugs was stupid, at least the part about weed. But it does open the door for serious pharmaceutical research, which means Regeneron Pharmaceuticals and other drug makers can now lobby the FDA to develop cannabis-derived medications. Which explains why Trump was suddenly photographed in the Oval Office on Thursday announcing a pricing deal with Regeneron, where the pharmaceutical giant agreed to reduce drug prices for Medicaid. Funny how a marijuana rescheduling announcement shows up the same day as a pharma company suddenly decides to play nice with federal pricing.

Why Did It Take So Long?

This is where it gets stupid. Trump signed the order. His attorney general supposedly agreed. The DEA was supposedly on board. And then… nothing happened. For months. The Washington Post reported that Trump actually expressed frustration at the "pace of easing federal restrictions on illegal drugs" just days before the announcement, suggesting he was annoyed his own people weren't moving fast enough on his own order.

Welcome to government in 2026, where the executive branch moves slower than a burnt-out postal worker on his last day before retirement.

The New York Times coverage noted that several officials within the Trump administration, including Robert Kennedy Jr. and other anti-vax healthcare figures in the cabinet, had been dragging their feet. Kennedy is now involved in pharmaceutical policy despite having zero relevant credentials beyond his famous distrust of, well, actual medicine. His presence in discussions about drug policy probably didn't help anything move faster.

Officials blamed "regulatory procedures" and "legal complexities," which is bureaucratic speak for "we were too lazy to fill out the forms." The DEA had to go through the motions of officially proposing the change, taking public comments, and pretending to consider what actual scientists and doctors said. By "pretending," we mean going through the legal motions that cost literally nothing but time.

What the Critics Are Already Saying

The pharmaceutical lobby is thrilled. Public health advocates are cautiously optimistic. Drug warriors in the Justice Department are reportedly devastated. And Congress, as usual, is doing absolutely nothing because they're too busy fighting about whose district gets the military base.

The real question is whether this reclassification means anything in practice. Schedule III drugs are still tightly controlled—researchers have to jump through federal hoops, get DEA approval, maintain detailed records, and basically prove they're not going to turn Stanford's biology department into a grow-op. It's better than Schedule I, but it's not like marijuana is suddenly going to be a normal prescription medication you pick up at CVS next to your blood pressure pills.

For the Trump administration, this is a W. They get to claim they actually delivered on a promise, even if it only took five months longer than it should have. For pharmaceutical companies, this is a major regulatory gift. For actual medical patients? It's probably fine. They'll see better research in five to ten years, assuming the government doesn't change its mind again when some other politician decides to be tough on drugs to look good during campaign season.

The Real Story Here

The stupid part isn't that Trump reclassified marijuana. The stupid part is that it took this long, that people acted like it was some massive accomplishment when it was literally an order he signed months ago that finally got implemented, and that the federal government has spent decades making it nearly impossible to study a plant that every serious medical researcher outside the U.S. has been investigating for years.

Meanwhile, states have been running their own programs, cannabis is being sold legally in stores across the country, and the federal government is finally catching up to what it could have admitted in 1970. Progress! At a glacial pace, but progress nonetheless.

Sources: Axios (April 22, 2026), The Washington Post (April 22, 2026), The New York Times (April 22-23, 2026), The Guardian (April 23, 2026)